A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy
Esophagus | Stomach
What is the purpose of this trial?
This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda.
There is no expanded access program available for the investigational agents per this protocol.
- Trial withOncologie, Inc.
- Start Date01/13/2020
- End Date12/31/2019
- Last Updated02/04/2020
- Study HIC#2000025859